gamma-aminobutyric acid has been researched along with Agoraphobia in 10 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Agoraphobia: Obsessive, persistent, intense fear of open places.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A randomized, double-blind, placebo-controlled, parallel-group study was conducted to evaluate the efficacy and safety of gabapentin in relieving the symptoms of panic disorder." | 9.09 | Placebo-controlled study of gabapentin treatment of panic disorder. ( Chouinard, G; Crockatt, J; Dager, SR; Greiner, M; Lydiard, RB; Pande, AC; Pollack, MH; Shiovitz, T; Taylor, CB, 2000) |
| "Low levels of gamma-aminobutyric acid (GABA) in plasma have been associated with the presence of mood disorders in patients with major depressive disorder." | 7.69 | Plasma levels of gamma-aminobutyric acid and panic disorder. ( Davis, LL; Germine, M; Goddard, AW; Kramer, GL; Narayan, M; Petty, F; Woods, SW, 1996) |
| "Sodium valproate (VA) and clonazepam (CLZ) were combined in the treatment of 4 patients with panic disorders (PD) who were resistant to several antipanic drug treatments." | 7.68 | Sodium valproate and clonazepam for treatment-resistant panic disorder. ( Fontaine, R; Ontiveros, A, 1992) |
| " A significant improvement was found in the symptomatology of these patients, but relapses occurred when CLZ dosage was reduced." | 5.28 | Sodium valproate and clonazepam for treatment-resistant panic disorder. ( Fontaine, R; Ontiveros, A, 1992) |
| "A randomized, double-blind, placebo-controlled, parallel-group study was conducted to evaluate the efficacy and safety of gabapentin in relieving the symptoms of panic disorder." | 5.09 | Placebo-controlled study of gabapentin treatment of panic disorder. ( Chouinard, G; Crockatt, J; Dager, SR; Greiner, M; Lydiard, RB; Pande, AC; Pollack, MH; Shiovitz, T; Taylor, CB, 2000) |
| "Pregabalin, a compound with a novel mechanism of action (MOA), has demonstrated efficacy as an adjunctive treatment for epilepsy and in several neuropathic pain models." | 4.83 | Pregabalin: From molecule to medicine. ( Kavoussi, R, 2006) |
| "To review pregabalin's pharmacology, pharmacokinetics, efficacy, and adverse effects in the treatment of neuropathic pain, epilepsy, and anxiety." | 4.82 | Pregabalin: a new neuromodulator with broad therapeutic indications. ( McAuley, JW; Shneker, BF, 2005) |
| " Key terms were anxiety, diabetic neuropathy, epilepsy, neuropathic pain, postherpetic neuralgia, pregabalin, and seizures." | 4.82 | Pregabalin: a new neuromodulator with broad therapeutic indications. ( McAuley, JW; Shneker, BF, 2005) |
| "Pfizer is developing pregabalin, a follow-up compound to its GABA agonist gabapentin, for the potential treatment of several central nervous system (CNS) disorders including epilepsy, neuropathic pain, anxiety and social phobia [286425]." | 4.81 | Pregabalin (Pfizer). ( Selak, I, 2001) |
| "There is preclinical evidence and indirect clinical evidence implicating gamma-aminobutyric acid (GABA) in the pathophysiology and treatment of human panic disorder." | 3.71 | Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. ( Almai, A; Behar, KL; Charney, DS; Goddard, AW; Krystal, JH; Mason, GF; Petroff, OA; Rothman, DL, 2001) |
| "Total occipital cortical GABA levels (GABA plus homocarnosine) were assessed in 14 unmedicated patients with panic disorder who did not have major depression and 14 retrospectively age- and sex-matched control subjects using spatially localized (1)H-magnetic resonance spectroscopy." | 3.71 | Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. ( Almai, A; Behar, KL; Charney, DS; Goddard, AW; Krystal, JH; Mason, GF; Petroff, OA; Rothman, DL, 2001) |
| "Patients with panic disorder had a 22% reduction in total occipital cortex GABA concentration (GABA plus homocarnosine) compared with controls." | 3.71 | Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. ( Almai, A; Behar, KL; Charney, DS; Goddard, AW; Krystal, JH; Mason, GF; Petroff, OA; Rothman, DL, 2001) |
| "Low levels of gamma-aminobutyric acid (GABA) in plasma have been associated with the presence of mood disorders in patients with major depressive disorder." | 3.69 | Plasma levels of gamma-aminobutyric acid and panic disorder. ( Davis, LL; Germine, M; Goddard, AW; Kramer, GL; Narayan, M; Petty, F; Woods, SW, 1996) |
| "Sodium valproate (VA) and clonazepam (CLZ) were combined in the treatment of 4 patients with panic disorders (PD) who were resistant to several antipanic drug treatments." | 3.68 | Sodium valproate and clonazepam for treatment-resistant panic disorder. ( Fontaine, R; Ontiveros, A, 1992) |
| "Panic disorder is associated with reductions in total occipital cortex GABA levels." | 1.31 | Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. ( Almai, A; Behar, KL; Charney, DS; Goddard, AW; Krystal, JH; Mason, GF; Petroff, OA; Rothman, DL, 2001) |
| " A significant improvement was found in the symptomatology of these patients, but relapses occurred when CLZ dosage was reduced." | 1.28 | Sodium valproate and clonazepam for treatment-resistant panic disorder. ( Fontaine, R; Ontiveros, A, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Waider, J | 1 |
| Popp, S | 1 |
| Lange, MD | 1 |
| Kern, R | 1 |
| Kolter, JF | 1 |
| Kobler, J | 1 |
| Donner, NC | 1 |
| Lowe, KR | 1 |
| Malzbender, JH | 1 |
| Brazell, CJ | 1 |
| Arnold, MR | 1 |
| Aboagye, B | 1 |
| Schmitt-Böhrer, A | 1 |
| Lowry, CA | 1 |
| Pape, HC | 1 |
| Lesch, KP | 1 |
| Stein, DJ | 1 |
| Bruce Lydiard, R | 1 |
| Herman, BK | 1 |
| Mandel, FS | 1 |
| Pigott, TA | 1 |
| Shneker, BF | 1 |
| McAuley, JW | 1 |
| Kavoussi, R | 1 |
| Goddard, AW | 2 |
| Narayan, M | 1 |
| Woods, SW | 1 |
| Germine, M | 1 |
| Kramer, GL | 1 |
| Davis, LL | 1 |
| Petty, F | 1 |
| Pande, AC | 1 |
| Pollack, MH | 1 |
| Crockatt, J | 1 |
| Greiner, M | 1 |
| Chouinard, G | 1 |
| Lydiard, RB | 1 |
| Taylor, CB | 1 |
| Dager, SR | 1 |
| Shiovitz, T | 1 |
| Mason, GF | 1 |
| Almai, A | 1 |
| Rothman, DL | 1 |
| Behar, KL | 1 |
| Petroff, OA | 1 |
| Charney, DS | 1 |
| Krystal, JH | 1 |
| Selak, I | 1 |
| Ontiveros, A | 1 |
| Fontaine, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Pregabalin and Duloxetine in Patients With Painful Diabetic Peripheral Neuropathy (PDPN): the Effect of Pain on Cognitive Function, Sleep and Quality of Life (BLOSSOM)[NCT04246619] | Phase 4 | 254 participants (Actual) | Interventional | 2019-11-12 | Terminated (stopped due to The statistical analysis will still provide relevant results with the same statistical power as initially planned.COVID-19 pandemic prolonged the recruiting period and consequently affected the costs of the clinical trial.) | ||
| Effect of Preoperative Pregabalin on Propofol Induction Dose[NCT01158859] | Phase 4 | 50 participants (Anticipated) | Interventional | 2010-04-30 | Completed | ||
| Effect of Gabapentin on Postoperative Opioid Analgesic Use and Pain in Adolescents Undergoing Tonsillectomy[NCT05024825] | Phase 4 | 17 participants (Actual) | Interventional | 2017-08-04 | Terminated (stopped due to recruitment target not met.) | ||
| The Role of Orexin in Human Panic Disorder[NCT02593682] | Phase 4 | 3 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for gamma-aminobutyric acid and Agoraphobia
| Article | Year |
|---|---|
Anxiety disorders in women.
Topics: Agoraphobia; Anti-Anxiety Agents; Anxiety Disorders; Comorbidity; Female; gamma-Aminobutyric Acid; H | 2003 |
Pregabalin: a new neuromodulator with broad therapeutic indications.
Topics: Agoraphobia; Anxiety; Diabetic Neuropathies; Epilepsy; gamma-Aminobutyric Acid; Herpesviridae Infect | 2005 |
Pregabalin: From molecule to medicine.
Topics: Agoraphobia; Animals; Anti-Anxiety Agents; Clinical Trials as Topic; gamma-Aminobutyric Acid; Humans | 2006 |
Pregabalin (Pfizer).
Topics: Agoraphobia; Animals; Anticonvulsants; Clinical Trials as Topic; Contraindications; GABA Agonists; g | 2001 |
1 trial available for gamma-aminobutyric acid and Agoraphobia
| Article | Year |
|---|---|
Placebo-controlled study of gabapentin treatment of panic disorder.
Topics: Acetates; Adolescent; Adult; Aged; Agoraphobia; Amines; Anti-Anxiety Agents; Cyclohexanecarboxylic A | 2000 |
5 other studies available for gamma-aminobutyric acid and Agoraphobia
| Article | Year |
|---|---|
Genetically driven brain serotonin deficiency facilitates panic-like escape behavior in mice.
Topics: Agoraphobia; Amygdala; Animals; Anxiety; Electroshock; Escape Reaction; Fear; gamma-Aminobutyric Aci | 2017 |
Impact of gastrointestinal symptoms on response to pregabalin in generalized anxiety disorder: results of a six-study combined analysis.
Topics: Adult; Agoraphobia; Analgesics; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as To | 2009 |
Plasma levels of gamma-aminobutyric acid and panic disorder.
Topics: Adult; Agoraphobia; Anxiety Disorders; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; M | 1996 |
Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy.
Topics: Adult; Agoraphobia; Ambulatory Care; Carnosine; Female; gamma-Aminobutyric Acid; Humans; Magnetic Re | 2001 |
Sodium valproate and clonazepam for treatment-resistant panic disorder.
Topics: Adult; Agoraphobia; Clonazepam; Drug Synergism; Drug Therapy, Combination; Female; gamma-Aminobutyri | 1992 |